{"id":41743,"date":"2019-03-28T09:44:19","date_gmt":"2019-03-28T14:44:19","guid":{"rendered":""},"modified":"2025-11-03T15:22:06","modified_gmt":"2025-11-03T20:22:06","slug":"evaluating-cost-effectiveness-cancer-drugs","status":"publish","type":"topics","link":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/evaluating-cost-effectiveness-cancer-drugs\/","title":{"rendered":"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux"},"content":{"rendered":"<p>Le co\u00fbt des m\u00e9dicaments anticanc\u00e9reux a fortement augment\u00e9 au cours de la derni\u00e8re d\u00e9cennie, et on s\u2019attend \u00e0 ce qu\u2019il continue de cro\u00eetre, comme l\u2019a indiqu\u00e9 Claire de Oliveira, experte en chef aupr\u00e8s du Partenariat canadien contre le cancer. Ces co\u00fbts \u00e9lev\u00e9s peuvent limiter l\u2019acc\u00e8s des patients \u00e0 des traitements efficaces. Lorsqu\u2019on prend des d\u00e9cisions concernant le financement des m\u00e9dicaments, il faut tenir compte du rapport co\u00fbt-efficacit\u00e9 et d\u2019autres facteurs importants, comme les avantages cliniques, la valeur pour les patients et l\u2019incidence budg\u00e9taire. L\u2019analyse du rapport co\u00fbt-efficacit\u00e9 aide \u00e0 peser les avantages suppl\u00e9mentaires d\u2019un nouveau traitement par rapport \u00e0 ses co\u00fbts suppl\u00e9mentaires.<\/p>\n<p>Le traitement du cancer du poumon offre un bon exemple des co\u00fbts. Les options de traitement et les co\u00fbts mensuels des m\u00e9dicaments ont fortement augment\u00e9 au cours de la derni\u00e8re d\u00e9cennie.<\/p>\n<blockquote><p>Malgr\u00e9 l\u2019augmentation des co\u00fbts de traitement, la survie globale \u00e0 5 ans des patients atteints d\u2019un cancer du poumon est rest\u00e9e obstin\u00e9ment inf\u00e9rieure \u00e0 20 %.<\/p><\/blockquote>\n<p>Cet article de revue analyse le rapport co\u00fbt-efficacit\u00e9 d\u2019un nouveau traitement du cancer du poumon. Le traitement peut potentiellement retarder la progression du cancer du poumon de 0,1\u00a0mois (11\u00a0mois contre 10,9\u00a0mois).<\/p>\n<p>Une meilleure compr\u00e9hension de l\u2019analyse co\u00fbt-efficacit\u00e9 aidera les oncologues \u00e0 concevoir des \u00e9tudes cliniques qui permettront d\u2019obtenir les donn\u00e9es n\u00e9cessaires. Ces donn\u00e9es pourraient mener \u00e0 des d\u00e9cisions plus \u00e9clair\u00e9es en mati\u00e8re de financement des m\u00e9dicaments et \u00e0 un meilleur acc\u00e8s \u00e0 des traitements efficaces.<\/p>\n<p>Lisez l\u2019article complet intitul\u00e9 \u00ab\u00a0<a href=\"https:\/\/www.jto.org\/article\/S1556-0864(17)30688-3\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\">Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals<\/a>\u00a0\u00bb [\u00e9valuer le rapport co\u00fbt-efficacit\u00e9\u00a0: un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux] (en anglais seulement)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le co\u00fbt des m\u00e9dicaments anticanc\u00e9reux a fortement augment\u00e9 au cours de la derni\u00e8re d\u00e9cennie, et on s\u2019attend \u00e0 ce qu\u2019il continue de cro\u00eetre, comme l\u2019a indiqu\u00e9 Claire de Oliveira, experte en chef aupr\u00e8s du Partenariat canadien contre le cancer. Ces co\u00fbts \u00e9lev\u00e9s peuvent limiter l\u2019acc\u00e8s des patients \u00e0 des traitements efficaces. Lorsqu\u2019on prend des d\u00e9cisions [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":0,"menu_order":0,"template":"","topics_tags":[],"type-of-care":[],"cancer-continuum":[],"cancer-system-measurement":[1790,1789],"dbt-cancer-site":[],"dbt-risk-factors":[],"dbt-population-characteristics":[],"class_list":["post-41743","topics","type-topics","status-publish","hentry","cancer-system-measurement-health-economics-fr","cancer-system-measurement-drug-funding-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canadian Partnership Against Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux - Canadian Partnership Against Cancer\" \/>\n<meta property=\"og:description\" content=\"Le co\u00fbt des m\u00e9dicaments anticanc\u00e9reux a fortement augment\u00e9 au cours de la derni\u00e8re d\u00e9cennie, et on s\u2019attend \u00e0 ce qu\u2019il continue de cro\u00eetre, comme l\u2019a indiqu\u00e9 Claire de Oliveira, experte en chef aupr\u00e8s du Partenariat canadien contre le cancer. Ces co\u00fbts \u00e9lev\u00e9s peuvent limiter l\u2019acc\u00e8s des patients \u00e0 des traitements efficaces. Lorsqu\u2019on prend des d\u00e9cisions [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&amp;p=41743\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Partnership Against Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T20:22:06+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@cancerstratca\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/?post_type=topics&p=41743\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/?post_type=topics&p=41743\",\"name\":\"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux - Canadian Partnership Against Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\"},\"datePublished\":\"2019-03-28T14:44:19+00:00\",\"dateModified\":\"2025-11-03T20:22:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/?post_type=topics&p=41743#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/?post_type=topics&p=41743\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/?post_type=topics&p=41743#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Topics\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/topics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\",\"url\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/\",\"name\":\"Canadian Partnership Against Cancer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canadian Partnership Against Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743","og_locale":"fr_FR","og_type":"article","og_title":"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux - Canadian Partnership Against Cancer","og_description":"Le co\u00fbt des m\u00e9dicaments anticanc\u00e9reux a fortement augment\u00e9 au cours de la derni\u00e8re d\u00e9cennie, et on s\u2019attend \u00e0 ce qu\u2019il continue de cro\u00eetre, comme l\u2019a indiqu\u00e9 Claire de Oliveira, experte en chef aupr\u00e8s du Partenariat canadien contre le cancer. Ces co\u00fbts \u00e9lev\u00e9s peuvent limiter l\u2019acc\u00e8s des patients \u00e0 des traitements efficaces. Lorsqu\u2019on prend des d\u00e9cisions [&hellip;]","og_url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743","og_site_name":"Canadian Partnership Against Cancer","article_publisher":"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/","article_modified_time":"2025-11-03T20:22:06+00:00","twitter_card":"summary_large_image","twitter_site":"@cancerstratca","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743","url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743","name":"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux - Canadian Partnership Against Cancer","isPartOf":{"@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website"},"datePublished":"2019-03-28T14:44:19+00:00","dateModified":"2025-11-03T20:22:06+00:00","breadcrumb":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/?post_type=topics&p=41743#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Topics","item":"https:\/\/www.partnershipagainstcancer.ca\/topics\/"},{"@type":"ListItem","position":2,"name":"\u00c9valuer le rapport co\u00fbt-efficacit\u00e9 : un \u00e9l\u00e9ment essentiel de l\u2019approbation des nouveaux m\u00e9dicaments anticanc\u00e9reux"}]},{"@type":"WebSite","@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website","url":"https:\/\/dev.partnershipagainstcancer.ca\/","name":"Canadian Partnership Against Cancer","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.partnershipagainstcancer.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/41743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/types\/topics"}],"author":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=41743"}],"wp:term":[{"taxonomy":"topics_tags","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics_tags?post=41743"},{"taxonomy":"type-of-care","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/type-of-care?post=41743"},{"taxonomy":"cancer-continuum","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-continuum?post=41743"},{"taxonomy":"cancer-system-measurement","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-system-measurement?post=41743"},{"taxonomy":"dbt-cancer-site","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-cancer-site?post=41743"},{"taxonomy":"dbt-risk-factors","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-risk-factors?post=41743"},{"taxonomy":"dbt-population-characteristics","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-population-characteristics?post=41743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}